RECRUITING

Weight Loss Management in Endometrial Cancer Survivors

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is being done to understand how oncologists can engage a multidisciplinary team to help endometrial cancer survivors with obesity to engage in a weight management program and potentially start a weight loss medication. Obesity often impacts the future health and longevity of early-stage endometrial cancer survivors more than their cancer diagnosis. Patients will be referred to the KUMC OB/Gyn weight management clinic to discuss weight management options. * If patients decide to use medications for weight loss, then the study will collect data from their chart that is recorded as part of routine monitoring for patients on weight loss medications. * If patients decide not to use any medications, the study will monitor physical exam and lab data collected as part of their routine medical care. The study will also try to understand reasons why patients did or did not start using a weight loss medication.

Official Title

Enacting Active Survivorship: Implementation of Weight Management Strategies in Endometrial Cancer Survivors

Quick Facts

Study Start:2025-03
Study Completion:2030-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06877572

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * ≥18 years old
  2. * ECOG 0-2
  3. * BMI ≥ 30kg/m2
  4. * Completed surgical staging with no evidence of residual disease
  5. * Endometrioid endometrial adenocarcinoma, p53 wild type
  6. * Stage 1
  7. * Undergoing active surveillance +/- brachytherapy
  1. * Unable to participate in behavior weight loss
  2. * Stroke, heart attack, end stage liver disease, or end stage kidney disease during the last 6 months.
  3. * Currently on a GLP-1 agonist
  4. * Currently on insulin

Contacts and Locations

Study Contact

Principal Investigator
CONTACT
913-588-0885
mjavellana@kumc.edu
Co-investigator
CONTACT
913-588-1593
yabedin@kumc.edu

Study Locations (Sites)

University of Kansas Medical Center
Kansas City, Kansas, 66160
United States

Collaborators and Investigators

Sponsor: University of Kansas Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03
Study Completion Date2030-10

Study Record Updates

Study Start Date2025-03
Study Completion Date2030-10

Terms related to this study

Keywords Provided by Researchers

  • Endometrial Cancer
  • Endometrial Cancer Survivors
  • Weight Management
  • GLP-1 agonist
  • naltrexone/bupropion
  • orlistat
  • phentermine/topiramate

Additional Relevant MeSH Terms

  • Endometrial Cancer Survivors
  • Weight Management
  • Early Stage Endometrial Cancer